November 2016
Dermatology
Web-Exclusive

Sign in to continue reading this article

Not registered? Create an account for free to read full articles on www.cliniciansbrief.com.

To access full articles on www.cliniciansbrief.com, please sign in below.

Busy? Sign in Faster. Sign into www.cliniciansbrief.com with your social media account.
...  Questions
Multiple Choice Questions
Questions  .../...
Score  .../...

Quiz: Atopy

Quiz: Atopy

Final score
... of ...
Take this quiz by answering the following multiple choice questions. Start Quiz
Quiz: Atopy
References and author information Show
References
  1. Halliwell RE. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol. 2006;15(114):207-208.
  2. Apoquel (oclacitinib tablet for dogs). Freedom of Information Summary: Original new animal drug application. NADA 141-345. http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDru....; published May 2013; accessed August 2015.
  3. Gonzales AJ, Bowman JW, Gici GJ, Zhang M, Mann DW, Mitton-Fry M. Oclacitinib (Apoquel) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324. 
  4. Collard WT, Hummel BD, Fielder AF, et al. The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. J Vet Pharmacol Ther. 2014;37(3):279-285. 
  5. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114.
  6. Apoquel (product label). Florham Park, NJ; Zoetis. https://www.zoetisus.com/_locale-assets/mcm-portal-assets/msds_pi/pi/apoquel.pdf accessed January 2015. 
Author

Clinician's Brief

Material from Clinician’s Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Up Next